Phoenix Financial Ltd. lifted its position in BrainsWay Ltd. (NASDAQ:BWAY - Free Report) by 100.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 482,724 shares of the company's stock after buying an additional 242,366 shares during the quarter. Phoenix Financial Ltd. owned about 2.56% of BrainsWay worth $4,552,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. ARK Investment Management LLC acquired a new position in shares of BrainsWay in the 4th quarter worth approximately $1,656,000. Sei Investments Co. acquired a new stake in shares of BrainsWay in the 4th quarter valued at $149,000. JPMorgan Chase & Co. increased its position in shares of BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company's stock worth $136,000 after purchasing an additional 11,221 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock valued at $207,000 after purchasing an additional 2,144 shares during the last quarter. 30.11% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of BrainsWay in a research note on Wednesday, March 12th.
Read Our Latest Stock Analysis on BWAY
BrainsWay Trading Up 0.4 %
Shares of BWAY traded up $0.03 during mid-day trading on Tuesday, hitting $8.35. 11,101 shares of the company traded hands, compared to its average volume of 72,600. The business has a 50-day moving average of $9.79 and a 200 day moving average of $9.83. BrainsWay Ltd. has a one year low of $4.61 and a one year high of $11.79. The stock has a market capitalization of $157.56 million, a price-to-earnings ratio of 83.51 and a beta of 1.17.
BrainsWay Profile
(
Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Recommended Stories
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
